Literature DB >> 32439027

Lewy Body Degenerations as Neuropsychiatric Disorders.

Jared T Hinkle1, Gregory M Pontone2.   

Abstract

Parkinson disease has historically been conceptualized as a movement disorder. In recent decades, nonmotor and neuropsychiatric symptoms have become increasingly recognized as being of paramount importance for patients with Parkinson disease. Neuropsychiatric phenomena dominate the course of the other major Lewy body disease, dementia with Lewy bodies. In this review, we survey the clinical relevance of nonmotor and neuropsychiatric symptoms to the heterogeneous presentations of Lewy body disease and their significance to ongoing research in this area. We consider how the nature of Lewy body neuropathology may help explicate the basis of nonmotor and neuropsychiatric symptoms in these two disorders.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Apathy; Cognitive impairment; Dementia with Lewy bodies; Depression; Parkinson disease; Psychosis; REM behavior disorder

Mesh:

Year:  2020        PMID: 32439027      PMCID: PMC7245581          DOI: 10.1016/j.psc.2020.02.003

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  149 in total

1.  Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.

Authors:  Michael Sommerauer; Tatyana D Fedorova; Allan K Hansen; Karoline Knudsen; Marit Otto; Jesper Jeppesen; Yoon Frederiksen; Jakob U Blicher; Jacob Geday; Adjmal Nahimi; Malene F Damholdt; David J Brooks; Per Borghammer
Journal:  Brain       Date:  2018-02-01       Impact factor: 13.501

2.  The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.

Authors:  A Breier; P H Berg
Journal:  Biol Psychiatry       Date:  1999-08-01       Impact factor: 13.382

3.  Neuropathology of dementia in a large cohort of patients with Parkinson's disease.

Authors:  Judit Horvath; François R Herrmann; Pierre R Burkhard; Constantin Bouras; Enikö Kövari
Journal:  Parkinsonism Relat Disord       Date:  2013-06-06       Impact factor: 4.891

4.  Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study.

Authors:  M Shiba; J H Bower; D M Maraganore; S K McDonnell; B J Peterson; J E Ahlskog; D J Schaid; W A Rocca
Journal:  Mov Disord       Date:  2000-07       Impact factor: 10.338

5.  A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Authors:  I H Richard; M P McDermott; R Kurlan; J M Lyness; P G Como; N Pearson; S A Factor; J Juncos; C Serrano Ramos; M Brodsky; C Manning; L Marsh; L Shulman; H H Fernandez; K J Black; M Panisset; C W Christine; W Jiang; C Singer; S Horn; R Pfeiffer; D Rottenberg; J Slevin; L Elmer; D Press; H C Hyson; W McDonald
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

Review 6.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease.

Authors:  Claire L Tomlinson; Rebecca Stowe; Smitaa Patel; Caroline Rick; Richard Gray; Carl E Clarke
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

7.  Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.

Authors:  J A Cooper; H J Sagar; S M Doherty; N Jordan; P Tidswell; E V Sullivan
Journal:  Brain       Date:  1992-12       Impact factor: 13.501

Review 8.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

9.  Clinical Markers of Anxiety Subtypes in Parkinson Disease.

Authors:  Martinus P G Broen; A F G Leentjens; J T Hinkle; A J H Moonen; M L Kuijf; N M Fischer; K Perepezko; A Bakker; G M Pontone
Journal:  J Geriatr Psychiatry Neurol       Date:  2018-03-11       Impact factor: 2.680

Review 10.  Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

Authors:  C H Williams-Gray; T Foltynie; C E G Brayne; T W Robbins; R A Barker
Journal:  Brain       Date:  2007-05-29       Impact factor: 13.501

View more
  2 in total

1.  Apathy and Anxiety in De Novo Parkinson's Disease Predict the Severity of Motor Complications.

Authors:  Jared T Hinkle; Kate Perepezko; Lorenzo L Gonzalez; Kelly A Mills; Gregory M Pontone
Journal:  Mov Disord Clin Pract       Date:  2020-12-04

2.  Long-acting paliperidone in Ekbom's syndrome in Lewy body dementia: A case report.

Authors:  Laura Orsolini; Diana Corona; Virginio Salvi; Umberto Volpe
Journal:  Transl Neurosci       Date:  2022-07-28       Impact factor: 1.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.